On the stock market since 2019, it operates in the world of health and science. It has 6,309 employees. Now — the numbers.
This is an established company with proven profits.
Average growth of 11% a year over the last 4 years. Every year shown ended in profit.
If every debt were paid off today, $511.9M would still be left in the vault — a solid cushion for hard times.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Bets Against the Stock: The number of investors betting on a fall stands out.
An investor who bought at the very peak is down 70% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The net profit margin is 16% — that slice of every sale is the company’s cushion in hard quarters.
Over the last 3 years, sales grew about 30% a year on average.
There is $2.1B in the vault; even if every debt were paid off, $511.9M would remain.
The stock sits at $0.49. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
The weight of investors positioned for a fall can be felt in the market. Council score: 2/10.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 3/10.
On our five-subject report card, IDGXF sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: IDGXF is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.